Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06771115 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
A Phase 2 study, sponsored by Zomagen Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT06771115 is a Phase 2 study that has completed, run by Zomagen Biosciences. The registered enrollment target is 176 participants.
The verdict
NCT06771115, a Phase 2 study, has completed, sponsored by Zomagen Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.
Interventions
- DRUG Placebo
- DRUG VTX3232 Dose A
- DRUG VTX3232 Dose A in combination with semaglutide
- DRUG Placebo in combination with semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06771115
The ClinicalTrials.gov registry entry for NCT06771115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zomagen Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06771115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06771115 about?
NCT06771115 is a clinical study titled "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity". This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This stu...
What is the current status of trial NCT06771115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2025-01-07. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT06771115?
The interventions under investigation include: Placebo (DRUG), VTX3232 Dose A (DRUG), VTX3232 Dose A in combination with semaglutide (DRUG), Placebo in combination with semaglutide (DRUG).
Who is sponsoring clinical trial NCT06771115?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.